Equity Overview
Price & Market Data
Price: $52.37
Daily Change: -$0.25 / 0.48%
Daily Range: $51.68 - $52.37
Market Cap: $6,073,052,672
Daily Volume: 550
Performance Metrics
1 Week: -0.49%
1 Month: 22.89%
3 Months: 34.27%
6 Months: 539.4%
1 Year: 2,531%
YTD: 30.25%
Company Details
Employees: 59
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.